cherry blossom

I remember when the test, Oncotype Dx, came on the horizon to aid in treatment decision making with a new diagnosis of breast cancer. I was working as a nurse navigator in a Breast Center in Las Vegas. In our monthly multidisciplinary conferences, the medical oncologists were somewhat apprehensive of relying on the test. Frankly, it was difficult for them not to offer chemotherapy to a newly diagnosed young woman or a woman found to have a large tumor, if indeed their Oncotype Dx score came back low. A low score would indicate neither one of these cases would benefit from being treated with chemotherapy. Much research and progress has been made with the genomic test over the past 10 years, and the article here indicates how it is now being considered in treatment of metastatic breast cancer.